KR-20260067456-A - Anti-aging composition containing 4-n-butylresorcinol, or gamma linolenic acid and 4-n-butylresorcinol water-soluble nanoliposome

Abstract

The present invention relates to a novel use of 4-n-butylresorcinol or gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes, and provides a composition having an anti-aging or skin improvement effect by promoting the expression of SIRT (SIRT1, etc.), known as a longevity gene.

Inventors

• 강윤아
• 김윤정
• 서수림

Assignees

• (주)에스앤케이연구센터

Dates

Publication Date

20260513

Application Date

20241105

Claims (6)

1. A composition for preventing or improving skin aging by promoting SIRT expression, comprising 4-n-butylresorcinol or gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes as an active ingredient.
2. A composition for preventing or improving skin aging, wherein, in claim 1, 4-n-butylresorcinol is included as an active ingredient, SIRT is SIRT1 or SIRT6.
3. A composition for preventing or improving skin aging according to claim 1, wherein, when gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes are included as an active ingredient, SIRT is SIRT1, SIRT3, SIRT6, or SIRT7.
4. In claim 1, the composition is a composition for preventing or improving skin aging, which is a cosmetic or pharmaceutical formulation.
5. A composition for preventing or improving skin aging, wherein, in claim 1, the content of 4-n-butylresorcinol or gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes in the total composition is 1 to 99 wt%.
6. A composition for preventing or improving skin aging, wherein the gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes in claim 1 are prepared by the step of mixing gamma-linolenic acid and 4-n-butylresorcinol with an emulsifier, an amino acid, and dextrin to form a water-soluble emulsion.

Description

Anti-aging composition for skin anti-aging or improvement containing 4-n-butylresorcinol or gamma linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes The present invention relates to a novel use of 4-n-butylresorcinol alone or water-soluble nanoliposomes of gamma-linolenic acid and 4-n-butylresorcinol (hereinafter referred to as "gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes"), and in particular, to a technology relating to a composition having an anti-aging or skin improvement effect. SIRT (Sirtuin, NAD(+)-dependent deacetylase) is a type of protein that has deacetylase enzymes including mono-ADP ribosyltransferase, desuccinylase, demalonylase, demyristoylase, and depalmitoylase activities. SIRT is a highly evolutionarily well-conserved protein present in almost all living organisms. Bacteria and archaea possess one or two SIRTs, whereas eukaryotes possess more. Among these, mammals have seven SIRTs (SIRT1–SIRT7); SIRT1, SIRT6, and SIRT7 are primarily located in the nucleus, SIRT2 in the cytosol, and SIRT3, SIRT4, and SIRT5 in the mitochondria. Among the seven types of SIRT mentioned above, SIRT1 is known to play roles in metabolic regulation, DNA repair, cell survival, and aging regulation; SIRT2 is known to play roles in nervous system protection and cell cycle regulation; SIRT3 to 5 are known to play roles in energy production, oxidative stress response, and amino acid metabolism; and SIRT6 and 7 are known to play roles in DNA repair and maintenance, aging regulation, and inflammatory response regulation. In particular, it has been known through various studies that SIRT1 is very closely related to the anti-aging effects of the skin. Looking at prior patent technologies related to such SIRT, Korean Patent Registration No. 10-1451357 disclosed a pharmaceutical composition for the prevention or treatment of sepsis or septic shock containing interferon beta, a SIRT1 expression inducing substance, as an active ingredient. Additionally, Korean Patent Registration No. 10-1991601 disclosed technology regarding a SIRT6 activating peptide. The inventors have registered a patent in Korean Patent Registration No. 10-0751883 for a whitening cosmetic composition containing "gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes" as an active ingredient, which prevents the browning phenomenon of 4-n-butylresorcinol that was a problem in the past by liposomalizing 4-n-butylresorcinol together with gamma-linolenic acid, thereby enhancing stability, and does not cause skin irritation even when used at high concentrations, and not only has the effect of reducing inflammation by gamma-linolenic acid but also has excellent whitening action by inhibiting melanin synthesis in cultured cells. Meanwhile, the inventors confirmed the effect of promoting SIRT (Sirtuin) expression as a novel effect other than the whitening effect of "4-n-butylresorcinol" or "gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes," and completed a composition having an anti-aging or skin improvement effect through the promotion of SIRT expression, particularly SIRT1 expression. Figure 1 shows the SIRT expression test results of 4-n-butylresosinol of Experimental Example 1. Figure 2 shows the results of the SIRT expression experiment of the gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes of Experimental Example 2. Figure 3 shows the results of the stem cell proliferation promotion experiment of gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes of Experimental Example 3. The present invention provides a composition for preventing or improving skin aging through a SIRT expression mechanism for 4-n-butylresorcinol or gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes. In addition, the content of 4-n-butylresorcinol or gamma-linolenic acid-4-n-butylresorcinol water-soluble nanoliposomes in the total composition may be 1 to 99 wt%, but may be adjusted outside the above range. Furthermore, the composition of the present invention may be prepared by adding various ingredients such as deionized water, alcohol, and fragrances depending on the formulation. In addition, the composition of the present invention may be prepared as a cosmetic or pharmaceutical composition formulation. In particular, in the case of cosmetics, it may be prepared as a skin toner, cream, spray, or gel that is applied directly to the skin. The effects of the present invention will be explained below through experiments. Experimental Example 1: SIRT expression experiment of 4-n-butylresosinol The experimental method of Experimental Example 1 is explained as follows. (1) Culture of fibroblasts Keratinocytes and fibroblasts were isolated from foreskin obtained through circumcision of young children. After removing residual subcutaneous fat from the skin tissue, it was finely incised and reacted in a thermolysin solution at 37°C for 30 minutes. The reacted tissue was sep